The healthcare giant beat second-quarter forecasts and raised its outlook.
Healthcare Bellwether J&J Beats And Raises, But Shares Dip
Licensing
08:48 AM ET 07/15/2026
Johnson & Johnson (JNJ) stock slumped early Wednesday after the healthcare giant reported adjusted earnings of $2.90 per share on $25.31 billion in second-quarter sales. On average, analysts polled by FactSet expected J&J to earn $2.85 a share and report $25.02 billion in sales. During the year-earlier period, Johnson & Johnson earned $2.77 per share on $23.74 billion in sales.…
Healthcare Stocks Stable Amid Broad Markets Rise — Healthcare Roundup
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
Johnson & Johnson eleva previsão anual após superar expectativas no 2º trimestre
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
Dow Jones Top Company Headlines at 7 AM ET: Johnson & Johnson Bumps Up Guidance as Sales Rise | BlackRock ...
Abbott Labs shares jump 12% as Q2 sales rise, profit outlook raised
Why Is Abbott Stock Skyrocketing Thursday? - Abbott Laboratories (NYSE:ABT)
UnitedHealth, Abbott Laboratories And 3 Stocks To Watch - UnitedHealth Group (NYSE:UNH)
Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Eli Lilly (NYSE
JNJ will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.05 billion.…
Stocks in the healthcare sector were flat amid a broader stock market rise.
Leerink analysts lifted J&J shares to a buy equivalent from hold on Wednesday, citing the company's slate of new drugs.
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
Shares of J&J rose about 1% Tuesday, shaking off their premarket declines.
J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and…
